B. Riley Wealth Advisors Inc. Acquires Shares of 873 Insulet Co. (NASDAQ:PODD)

B. Riley Wealth Advisors Inc. bought a new position in shares of Insulet Co. (NASDAQ:PODD) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 873 shares of the medical instruments supplier’s stock, valued at approximately $202,000.

Several other hedge funds have also recently modified their holdings of PODD. Blue Trust Inc. increased its stake in Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 58 shares in the last quarter. Venturi Wealth Management LLC boosted its stake in shares of Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 133 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in shares of Insulet during the second quarter worth approximately $32,000. UMB Bank n.a. raised its stake in Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 81 shares during the last quarter. Finally, TD Private Client Wealth LLC lifted its holdings in Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 56 shares in the last quarter.

Insulet Trading Up 3.9 %

NASDAQ PODD opened at $266.57 on Monday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a market capitalization of $18.70 billion, a P/E ratio of 45.65, a PEG ratio of 4.12 and a beta of 1.21. The firm’s 50-day moving average is $254.48 and its two-hundred day moving average is $223.25. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.77.

Insider Activity

In related news, CAO Lauren Budden sold 915 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.47% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on PODD shares. Canaccord Genuity Group increased their target price on shares of Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Citigroup increased their price objective on shares of Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. BTIG Research boosted their target price on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Barclays increased their price target on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Finally, JPMorgan Chase & Co. boosted their price objective on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research note on Thursday, December 12th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $269.40.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.